Cycloserine
Antibiotics
- Drug class
- Antibiotics
- Availability
- See label
- Markets covered
- 1
- Products on record
- 1
Overview
Cycloserine is an active pharmaceutical ingredient in the Antibiotics group (J04AB). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 1 | March 6, 2026 |
GBUnited Kingdom· MHRA
1 product
Uses
Actions:
Cycloserine inhibits cell wall synthesis in susceptible strains of Gram-positive and Gram-negative bacteria and in Mycobacterium tuberculosis. Indications. Cycloserine is indicated in the treatment of active pulmonary and extra-pulmonary tuberculosis (including renal disease) when the organisms are susceptible to this drug and after failure of adequate treatment with the primary medications (streptomycin, isoniazid, rifampicin and ethambutol).
Like all anti-tuberculous drugs, cyclosenne should be administered in conjunction with other effective chemotherapy and not as the sole therapeutic agent. Cycloserine may be effective in the treatment of acute urinary tract infections caused by susceptible strains of Gram-positive and Gram-negative bacteria, especially Klebsiella/Enterobacter species and Escherichia coli.
It is generally no more and may be less effective than other antimicrobial agents in the treatment of urinary tract infections caused by bacteria other than mycobacteria, Use of cycloserine in these infections should be considered only when the more conventional therapy has failed and when the organism has been demonstrated to be sensitive to the drug.
Drug interactions
Known interactions involving Cycloserine. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL450430109 · revised March 6, 2026
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.